

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representations to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



BBI LIFE SCIENCES CORPORATION

BBI 生命科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1035)

**CLARIFICATION ANNOUNCEMENT ON
GRANT OF SHARE OPTIONS**

Reference is made to the announcement (the “**Announcement**”) of BBI Life Sciences Corporation (the “**Company**”) dated 24 April 2018 in relation to the grant of share options. Under otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company wishes to clarify that due to inadvertent clerical error, the Validity period of the Options was incorrectly stated as “24 April 2018 to 23 April 2023, both dates inclusive” in the Announcement, and the correct Validity period of the Options shall be “24 April 2018 to 24 April 2028, both dates inclusive”.

Save as disclosed above, the Company confirms that all other information in the Announcement remains accurate.

By order of the Board
BBI Life Sciences Corporation
Wang Qisong
Chairmen

Hong Kong, 15 May 2018

As at the date of this announcement, the executive Directors are Mr. WANG Qisong, Ms. WANG Luojia and Ms. WANG Jin; the non-executive Director is Mr. ZHOU Mi; and the independent non-executive Directors are Mr. XIA Lijun, Mr. HO Kenneth Kai Chung and Mr. LIU Jianjun.